{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:24:23Z","timestamp":1789698263007,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pnpbp.2026.111651","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:51:29Z","timestamp":1772207489000},"page":"111651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ketamine pharmacotherapy for major depressive disorder: A narrative review"],"prefix":"10.1016","volume":"145","author":[{"given":"Chris H.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Baten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulaikha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saneh K.","family":"Kahlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah H.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Venegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Sacchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawson W.","family":"Hedges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111651_bb0005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review and meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0010","first-page":"e586","article-title":"Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111651_bb0015","article-title":"Combination of transcranial magnetic stimulation and ketamine in treatment-resistant depression: a systematic review","volume":"16","author":"Arubuolawe","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0020","first-page":"411","article-title":"Efficacy of intravenous ketamine and intranasal esketamine for treatment-resistant depression: a systematic review and meta-analysis","volume":"276","author":"Bahji","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0025","first-page":"340","article-title":"Intranasal esketamine (Spravato) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0030","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine's antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111651_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0040","article-title":"Unveiling the anti-inflammatory effects of antidepressants: ketamine and related mechanisms in depression","volume":"18","author":"Bleibel","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111651_bb0045","article-title":"Safety and effectiveness of intranasal esketamine for patients with treatment-resistant depression in real-world clinical practice: a systematic review of observational studies","volume":"15","author":"Boudieu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0050","first-page":"409","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"357","author":"Can","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.657714","article-title":"Repurposing ketamine in depression and related disorders","volume":"15","author":"Carboni","year":"2021","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0060","article-title":"Effectiveness and safety of esketamine in patients with treatment-resistant depression in real-world clinical practice: results from the REAL-ESK observational study","volume":"83","author":"Castro","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae058","article-title":"Real-world safety of esketamine nasal spray: a comprehensive analysis of esketamine and respiratory depression","volume":"27","author":"Chepke","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/cns.12063","article-title":"From \u201cSpecial K\u201d to \u201cSpecial M\u201d: the evolution of the recreational use of ketamine and methoxetamine","volume":"19","author":"Corazza","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0075","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatr."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: relapse prevention","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acschemneuro.2c00637","article-title":"Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin","volume":"14","author":"Davoudian","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","article-title":"Metabolism and metabolomics of ketamine: a toxicological approach","volume":"2","author":"Dinis-Oliveira","year":"2017","journal-title":"Forensic Sci. Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111651_bb0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111651_bb0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"9","author":"Ferrari","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0110","article-title":"Esketamine\u2019s regulatory journey and evidence for use in treatment-resistant depression: a critical review","volume":"29","author":"Fitzgerald","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0115","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"15","key":"10.1016\/j.pnpbp.2026.111651_bb0120","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111651_bb0130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/aps.2016.5","article-title":"Ketamine use in current clinical practice","volume":"37","author":"Gao","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0140","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42141-5","article-title":"Ketamine's acute effects on negative brain states are mediated through distinct altered states of consciousness in humans","volume":"14","author":"Hack","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0150","article-title":"Hydroxynorketamines: pharmacology and potential therapeutic applications","volume":"223","author":"Highland","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicidal ideation with intent: results of a phase\u00a03, randomized study (ASPIRE\u00a0II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0165","series-title":"SPRAVATO\u00ae (Esketamine) Nasal Spray, for Intranasal Use [Prescribing Information]","author":"Janssen Pharmaceuticals, Inc","year":"2020"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0170","series-title":"SPRAVATO\u00ae (Esketamine) Nasal Spray, for Intranasal Use [Prescribing Information]","author":"Janssen Pharmaceuticals, Inc.","year":"2020"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0175","author":"Janssen Research & Development"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0180","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/archpsyc.55.8.694","article-title":"A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders","volume":"55","author":"Judd","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111651_bb0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bja.2020.06.067","article-title":"Ketamine pharmacokinetics: a meta-analysis and model-based approach","volume":"125","author":"Kamp","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0190","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-025-02041-9","article-title":"Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders","author":"Kavakbasi","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archpsyc.1992.01820100053010","article-title":"Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects","volume":"49","author":"Keller","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"23","key":"10.1016\/j.pnpbp.2026.111651_bb0200","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0205","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41593-021-00868-8","article-title":"Sustained antidepressant effects of ketamine and scopolamine require BDNF-dependent MeCP2 phosphorylation at Ser421","volume":"24","author":"Kim","year":"2021","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0210","first-page":"273","article-title":"Role of dopamine in reward and reinforcement: implications for the use of psychostimulants in psychiatry","volume":"32","author":"Kokkinou","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111651_bb0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13651501.2016.1254802","article-title":"Administration of ketamine for unipolar and bipolar depression","volume":"21","author":"Kraus","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111651_bb0220","first-page":"1525","article-title":"Efficacy and safety of ketamine in the treatment of depression: a systematic review and meta-analysis of randomized controlled trials","volume":"237","author":"Kryst","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111651_bb0230","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1111\/bcp.15467","article-title":"Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant: implications for precision dosing in a global perspective","volume":"88","author":"Langmia","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0235","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2147\/NDT.S388764","article-title":"Efficacy and safety of esketamine combined with antidepressants for treatment-resistant depression: a meta-analysis","volume":"18","author":"Liu","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"22","key":"10.1016\/j.pnpbp.2026.111651_bb0240","article-title":"Neuroinflammation mechanisms of neuromodulation for depression treatment: targeting microglia, inflammasome, and cytokine pathways","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0245","first-page":"47","article-title":"The anti-inflammatory effects of ketamine: state of the art","volume":"62","author":"Loix","year":"2011","journal-title":"Acta Anaesthesiol. Belg."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111651_bb0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of \u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0255","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment-resistant depression: January 2009\u2013January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0260","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2024.05.131","article-title":"At-home, telehealth-supported ketamine treatment for depression: findings from longitudinal, machine learning and symptom network analysis of real-world data","volume":"361","author":"Mathai","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111651_bb0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0270","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S2215-0366(23)00183-9","article-title":"Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies","volume":"10","author":"Medeiros","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111651_bb0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.31887\/DCNS.2008.10.4\/jmendlewicz","article-title":"Towards achieving remission in the treatment of depression","volume":"10","author":"Mendlewicz","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0280","article-title":"Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric and knowledge mapping analysis","volume":"15","author":"Miao","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0285","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111651_bb0290","first-page":"693","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0295","first-page":"149","article-title":"Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation","volume":"5","author":"Morgan","year":"2014","journal-title":"Front. Psychol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"HV journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0305","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083558","article-title":"The behavioral and neuroinflammatory impact of ketamine in a murine model of depression and liver damage","volume":"26","author":"Mu\u015fat","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0315","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jpsychires.2024.11.010","article-title":"Intranasal esketamine for patients with major depressive disorder: a systematic review and meta-analysis","volume":"180","author":"Oraee","year":"2024","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111651_bb0325","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041495","article-title":"Efficacy of esketamine nasal spray for treatment-resistant depression: a meta-analysis of randomized controlled studies","volume":"104","author":"Ouyang","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111651_bb0330","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/03007995.2016.1277201","article-title":"Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis","volume":"33","author":"Papadimitropoulou","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0335","series-title":"Ketalar (ketamine hydrochloride) injection, for intravenous or intramuscular use [prescribing information]","author":"Par Sterile Products, LLC","year":"2020"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111651_bb0340","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/neu.2017.39","article-title":"A brief history of antidepressant drug development: from tricyclics to beyond ketamine","volume":"30","author":"Pereira","year":"2018","journal-title":"Acta Neuropsychiatr."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0345","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/npp.2010.166","article-title":"Frontocingulate dysfunction in depression: toward biomarkers of treatment response","volume":"36","author":"Pizzagalli","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111651_bb0350","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0355","first-page":"505","article-title":"Ketamine and the evolution of rapid-acting antidepressants: from bench to bedside and back again","volume":"17","author":"Riggins","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111651_bb0360","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111651_bb0365","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/a-1714-9097","article-title":"Novel antidepressants in the pipeline (phase II and III): a systematic review of the US clinical trials registry","volume":"55","author":"Sakurai","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0370","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of esketamine nasal spray: a comprehensive analysis of esketamine and respiratory depression","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0375","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111651_bb0380","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00213-024-06573-1","article-title":"Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study","volume":"241","author":"Shanok","year":"2024","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0390","first-page":"750","article-title":"Ketamine-based anesthesia versus non-ketamine anesthesia during ECT for treatment-resistant depression: a systematic review and network meta-analysis","volume":"29","author":"Sicignano","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0395","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111651_bb0400","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/HRP.0000000000000312","article-title":"Neurocognitive effects of ketamine and esketamine for treatment-resistant major depressive disorder: a systematic review","volume":"29","author":"Souza-Marques","year":"2021","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2022.795231","article-title":"Brain changes associated with long-term ketamine abuse, a systematic review","volume":"16","author":"Strous","year":"2022","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0410","first-page":"339","article-title":"Antidepressant effect of ketamine on inflammation: a systematic review and meta-analysis of clinical studies","volume":"150","author":"Sukhram","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0415","article-title":"Comparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation, and electroconvulsive therapy for stage\u00a02 or higher treatment-resistant depression: a systematic review and network meta-analysis","volume":"4","author":"Terao","year":"2025","journal-title":"Psychiatr. Clin. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine\u2019s effect on serotonin\u2081B receptor binding in patients with SSRI-resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0430","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs esketamine vs lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111651_bb0435","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","article-title":"Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review","volume":"24","author":"Veraart","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0440","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0445","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2022","journal-title":"BJPsych Open."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111651_bb0450","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother. Psychosom."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111651_bb0455","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"15","key":"10.1016\/j.pnpbp.2026.111651_bb0460","article-title":"Ketamine research trends and its expanding relevance in psychiatric disorders","volume":"2023","author":"Yavi","year":"2022","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111651_bb0465","first-page":"675","article-title":"Interactions between the opioid and glutamate systems in depression: clinical and preclinical evidence","volume":"88","author":"Yoon","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0470","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"7604","key":"10.1016\/j.pnpbp.2026.111651_bb0475","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111651_bb0480","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111651_bb0485","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0490","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0014-2999(92)90248-3","article-title":"Differential effects of ketamine enantiomers on N-methyl-D-aspartate receptor-activated cation currents in cultured neurons","volume":"213","author":"Zeilhofer","year":"1992","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0495","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1515\/tnsci-2020-0167","article-title":"Immunoregulation and antidepressant effect of ketamine","volume":"12","author":"Zhang","year":"2021","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111651_bb0500","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1515\/tnsci-2020-0167","article-title":"Immunoregulation and antidepressant effect of ketamine","volume":"12","author":"Zhang","year":"2021","journal-title":"Transl. Neurosci."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111651_bb0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptor\u2013mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111651_bb0510","article-title":"Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric and visual analysis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111651_bb0515","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","article-title":"Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant effects","volume":"84","author":"Pham","year":"2018","journal-title":"Biol. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:39:30Z","timestamp":1776494370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":101,"alternative-id":["S0278584626000473"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111651","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine pharmacotherapy for major depressive disorder: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111651"}}